NEUROSENSE THERAPEUTICS LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -0.79% |
|
-11.97% | +59.24% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.84M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M | Net income 2025 * | -16M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.53
x | P/E ratio 2025 * |
-1.57
x | Employees | 18 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.44% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.79% | ||
| 1 week | -11.97% | ||
| Current month | -31.32% | ||
| 1 month | -26.47% | ||
| 3 months | +22.55% | ||
| 6 months | +165.11% | ||
| Current year | +59.24% |
1 week
1.11
1.50
1 month
1.112.25
Current year
0.762.33
1 year
0.402.33
3 years
0.408.18
5 years
0.408.18
10 years
0.408.18
| Managers | Title | Age | Since |
|---|---|---|---|
Alon Ben-Noon
FOU | Founder | 45 | 17-02-12 |
Or Eisenberg
DFI | Director of Finance/CFO | 42 | 21-05-31 |
Hagit Binder
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 21-12-20 | |
| Chairman | 67 | 21-09-30 | |
Cary Claiborne
BRD | Director/Board Member | 64 | 21-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.25 | -0.79% | 35 690 |
| 24-04-25 | 1.26 | -5.97% | 139,169 |
| 24-04-24 | 1.34 | -1.47% | 132,972 |
| 24-04-23 | 1.36 | +0.74% | 79,111 |
| 24-04-22 | 1.35 | -4.93% | 355,888 |
Delayed Quote Nasdaq, April 26, 2024 at 02:06 pm EDT
More quotes
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.26
USD
Average target price
5.25
USD
Spread / Average Target
+316.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.24% | 21.84M | |
| -1.91% | 103B | |
| +0.80% | 95.71B | |
| +1.69% | 22.02B | |
| -17.10% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -15.09% | 15.52B | |
| +3.67% | 13.86B | |
| +34.93% | 12.04B |
- Stock Market
- Equities
- NRSN Stock
